These results showed that, with the exception of lymph node status, and tumor size, the combined TP53 genomic information contributed significantly in a Cox proportional hazards model to associate with patients’ DMFS, than the other clinicopathological markers (HR, 1.84; 95% CI, 1.30–2.61; p = 6.3 × 10−4 for tumor size; HR, 4.18; 95% CI, 1.50–11.64; p = 6.2 × 10−3 for lymph node status; HR, 4.61; 95% CI, 1.94–10.95; p = 5.4 × 10−4 for TP53 mutation status; HR, 1.65; 95% CI, 1.18–2.32; p = 3.6 × 10−3 for TP53t2/t1 ratio; Table 3). The gene discussed is TP53; the disease is neoplasm.